Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum

Shaun B. Reeksting, Ingrid B. Müller, Pieter B. Burger, Emmanuel S. Burgos, Laurent Salmon, Abraham I. Louw, Lyn Marie Birkholtz, Carsten Wrenger

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Malaria tropica is a devastating infectious disease caused by Plasmodium falciparum. This parasite synthesizes vitamin B6 de novo via the PLP (pyridoxal 5′-phosphate) synthase enzymatic complex consisting of PfPdx1 and PfPdx2 proteins. Biosynthesis of PLP is largely performed by PfPdx1, ammonia provided by PfPdx2 subunits is condensed together with R5P (D-ribose 5-phosphate) and G3P (DL-glyceraldehyde 3-phosphate). PfPdx1 accommodates both the R5P and G3P substrates and intricately co-ordinates the reaction mechanism, which is composed of a series of imine bond formations, leading to the production of PLP. We demonstrate that E4P (D-erythrose 4-phosphate) inhibits PfPdx1 in a dose-dependent manner. We propose that the acyclic phospho-sugar E4P, with a C1 aldehyde group similar to acyclic R5P, could interfere with R5P imine bond formations in the PfPdx1 reaction mechanism. Molecular docking and subsequent screening identified the E4P hydrazide analogue 4PEHz (4-phospho-D-erythronhydrazide), which selectively inhibited PfPdx1 with an IC50 of 43 μM. PfPdx1 contained in the heteromeric PLP synthase complex was shown to be more sensitive to 4PEHz and was inhibited with an IC50 of 16 μM. Moreover, the compound had an IC50 value of 10 μM against cultured P. falciparum intraerythrocytic parasites. To analyse further the selectivity of 4PEHz, transgenic cell lines overexpressing PfPdx1 and PfPdx2 showed that additional copies of the protein complex conferred protection against 4PEHz, indicating that the PLP synthase is directly affected by 4PEHz in vivo. These PfPdx1 inhibitors represent novel lead scaffolds which are capable of targeting PLP biosynthesis, and we propose this as a viable strategy for the development of new therapeutics against malaria.

Original languageEnglish (US)
Pages (from-to)175-187
Number of pages13
JournalBiochemical Journal
Volume449
Issue number1
DOIs
StatePublished - Jan 1 2013

Fingerprint

Pyridoxal Phosphate
Falciparum Malaria
Parasites
Glyceraldehyde 3-Phosphate
Inhibitory Concentration 50
Imines
Biosynthesis
Plasmodium falciparum
Malaria
Vitamin B 6
Ammonia
Aldehydes
Scaffolds
Sugars
Communicable Diseases
Screening
Proteins
Cells
Cell Line
ribose-5-phosphate

Keywords

  • D-erythrose 4-phosphate (E4P)
  • Pdx1
  • Plasmodium falciparum
  • PLP synthase
  • Pyridoxal 5′-phosphate (PLP)
  • Vitamin B

ASJC Scopus subject areas

  • Biochemistry
  • Cell Biology
  • Molecular Biology

Cite this

Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum. / Reeksting, Shaun B.; Müller, Ingrid B.; Burger, Pieter B.; Burgos, Emmanuel S.; Salmon, Laurent; Louw, Abraham I.; Birkholtz, Lyn Marie; Wrenger, Carsten.

In: Biochemical Journal, Vol. 449, No. 1, 01.01.2013, p. 175-187.

Research output: Contribution to journalArticle

Reeksting, SB, Müller, IB, Burger, PB, Burgos, ES, Salmon, L, Louw, AI, Birkholtz, LM & Wrenger, C 2013, 'Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum', Biochemical Journal, vol. 449, no. 1, pp. 175-187. https://doi.org/10.1042/BJ20120925
Reeksting, Shaun B. ; Müller, Ingrid B. ; Burger, Pieter B. ; Burgos, Emmanuel S. ; Salmon, Laurent ; Louw, Abraham I. ; Birkholtz, Lyn Marie ; Wrenger, Carsten. / Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum. In: Biochemical Journal. 2013 ; Vol. 449, No. 1. pp. 175-187.
@article{5c938c8859c34562bb1c7df3b3aefeac,
title = "Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum",
abstract = "Malaria tropica is a devastating infectious disease caused by Plasmodium falciparum. This parasite synthesizes vitamin B6 de novo via the PLP (pyridoxal 5′-phosphate) synthase enzymatic complex consisting of PfPdx1 and PfPdx2 proteins. Biosynthesis of PLP is largely performed by PfPdx1, ammonia provided by PfPdx2 subunits is condensed together with R5P (D-ribose 5-phosphate) and G3P (DL-glyceraldehyde 3-phosphate). PfPdx1 accommodates both the R5P and G3P substrates and intricately co-ordinates the reaction mechanism, which is composed of a series of imine bond formations, leading to the production of PLP. We demonstrate that E4P (D-erythrose 4-phosphate) inhibits PfPdx1 in a dose-dependent manner. We propose that the acyclic phospho-sugar E4P, with a C1 aldehyde group similar to acyclic R5P, could interfere with R5P imine bond formations in the PfPdx1 reaction mechanism. Molecular docking and subsequent screening identified the E4P hydrazide analogue 4PEHz (4-phospho-D-erythronhydrazide), which selectively inhibited PfPdx1 with an IC50 of 43 μM. PfPdx1 contained in the heteromeric PLP synthase complex was shown to be more sensitive to 4PEHz and was inhibited with an IC50 of 16 μM. Moreover, the compound had an IC50 value of 10 μM against cultured P. falciparum intraerythrocytic parasites. To analyse further the selectivity of 4PEHz, transgenic cell lines overexpressing PfPdx1 and PfPdx2 showed that additional copies of the protein complex conferred protection against 4PEHz, indicating that the PLP synthase is directly affected by 4PEHz in vivo. These PfPdx1 inhibitors represent novel lead scaffolds which are capable of targeting PLP biosynthesis, and we propose this as a viable strategy for the development of new therapeutics against malaria.",
keywords = "D-erythrose 4-phosphate (E4P), Pdx1, Plasmodium falciparum, PLP synthase, Pyridoxal 5′-phosphate (PLP), Vitamin B",
author = "Reeksting, {Shaun B.} and M{\"u}ller, {Ingrid B.} and Burger, {Pieter B.} and Burgos, {Emmanuel S.} and Laurent Salmon and Louw, {Abraham I.} and Birkholtz, {Lyn Marie} and Carsten Wrenger",
year = "2013",
month = "1",
day = "1",
doi = "10.1042/BJ20120925",
language = "English (US)",
volume = "449",
pages = "175--187",
journal = "Biochemical Journal",
issn = "0264-6021",
publisher = "Portland Press Ltd.",
number = "1",

}

TY - JOUR

T1 - Exploring inhibition of Pdx1, a component of the PLP synthase complex of the human malaria parasite Plasmodium falciparum

AU - Reeksting, Shaun B.

AU - Müller, Ingrid B.

AU - Burger, Pieter B.

AU - Burgos, Emmanuel S.

AU - Salmon, Laurent

AU - Louw, Abraham I.

AU - Birkholtz, Lyn Marie

AU - Wrenger, Carsten

PY - 2013/1/1

Y1 - 2013/1/1

N2 - Malaria tropica is a devastating infectious disease caused by Plasmodium falciparum. This parasite synthesizes vitamin B6 de novo via the PLP (pyridoxal 5′-phosphate) synthase enzymatic complex consisting of PfPdx1 and PfPdx2 proteins. Biosynthesis of PLP is largely performed by PfPdx1, ammonia provided by PfPdx2 subunits is condensed together with R5P (D-ribose 5-phosphate) and G3P (DL-glyceraldehyde 3-phosphate). PfPdx1 accommodates both the R5P and G3P substrates and intricately co-ordinates the reaction mechanism, which is composed of a series of imine bond formations, leading to the production of PLP. We demonstrate that E4P (D-erythrose 4-phosphate) inhibits PfPdx1 in a dose-dependent manner. We propose that the acyclic phospho-sugar E4P, with a C1 aldehyde group similar to acyclic R5P, could interfere with R5P imine bond formations in the PfPdx1 reaction mechanism. Molecular docking and subsequent screening identified the E4P hydrazide analogue 4PEHz (4-phospho-D-erythronhydrazide), which selectively inhibited PfPdx1 with an IC50 of 43 μM. PfPdx1 contained in the heteromeric PLP synthase complex was shown to be more sensitive to 4PEHz and was inhibited with an IC50 of 16 μM. Moreover, the compound had an IC50 value of 10 μM against cultured P. falciparum intraerythrocytic parasites. To analyse further the selectivity of 4PEHz, transgenic cell lines overexpressing PfPdx1 and PfPdx2 showed that additional copies of the protein complex conferred protection against 4PEHz, indicating that the PLP synthase is directly affected by 4PEHz in vivo. These PfPdx1 inhibitors represent novel lead scaffolds which are capable of targeting PLP biosynthesis, and we propose this as a viable strategy for the development of new therapeutics against malaria.

AB - Malaria tropica is a devastating infectious disease caused by Plasmodium falciparum. This parasite synthesizes vitamin B6 de novo via the PLP (pyridoxal 5′-phosphate) synthase enzymatic complex consisting of PfPdx1 and PfPdx2 proteins. Biosynthesis of PLP is largely performed by PfPdx1, ammonia provided by PfPdx2 subunits is condensed together with R5P (D-ribose 5-phosphate) and G3P (DL-glyceraldehyde 3-phosphate). PfPdx1 accommodates both the R5P and G3P substrates and intricately co-ordinates the reaction mechanism, which is composed of a series of imine bond formations, leading to the production of PLP. We demonstrate that E4P (D-erythrose 4-phosphate) inhibits PfPdx1 in a dose-dependent manner. We propose that the acyclic phospho-sugar E4P, with a C1 aldehyde group similar to acyclic R5P, could interfere with R5P imine bond formations in the PfPdx1 reaction mechanism. Molecular docking and subsequent screening identified the E4P hydrazide analogue 4PEHz (4-phospho-D-erythronhydrazide), which selectively inhibited PfPdx1 with an IC50 of 43 μM. PfPdx1 contained in the heteromeric PLP synthase complex was shown to be more sensitive to 4PEHz and was inhibited with an IC50 of 16 μM. Moreover, the compound had an IC50 value of 10 μM against cultured P. falciparum intraerythrocytic parasites. To analyse further the selectivity of 4PEHz, transgenic cell lines overexpressing PfPdx1 and PfPdx2 showed that additional copies of the protein complex conferred protection against 4PEHz, indicating that the PLP synthase is directly affected by 4PEHz in vivo. These PfPdx1 inhibitors represent novel lead scaffolds which are capable of targeting PLP biosynthesis, and we propose this as a viable strategy for the development of new therapeutics against malaria.

KW - D-erythrose 4-phosphate (E4P)

KW - Pdx1

KW - Plasmodium falciparum

KW - PLP synthase

KW - Pyridoxal 5′-phosphate (PLP)

KW - Vitamin B

UR - http://www.scopus.com/inward/record.url?scp=84870875476&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870875476&partnerID=8YFLogxK

U2 - 10.1042/BJ20120925

DO - 10.1042/BJ20120925

M3 - Article

VL - 449

SP - 175

EP - 187

JO - Biochemical Journal

JF - Biochemical Journal

SN - 0264-6021

IS - 1

ER -